Fulcrum Therapeutics® Announces Multiple Presentations on FSHD at the American Academy of Neurology’s Annual Meeting
April 01, 2022 08:30 ET
|
Fulcrum Therapeutics, Inc.
Presentations highlight potential of losmapimod to slow or stop progression of FSHD Company on track to initiate Phase 3 REACH trial in 2Q 2022 CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) --...
Fulcrum Therapeutics® to Host Virtual Key Opinion Leader Webcast Featuring Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)
March 17, 2022 08:00 ET
|
Fulcrum Therapeutics, Inc.
Event to discuss unmet need in FSHD, key measures of disease progression and Phase 3 REACH trial Live webcast March 24, 2022 at 10:00am ET CAMBRIDGE, Mass., March 17, 2022 (GLOBE...
Fulcrum Therapeutics® Presents Data Highlighting Reachable Workspace (RWS) as Relevant Functional Endpoint in Facioscapulohumeral Muscular Dystrophy (FSHD) at MDA Clinical and Scientific Conference
March 14, 2022 08:00 ET
|
Fulcrum Therapeutics, Inc.
RWS has been correlated with ability to perform activities of daily living and maintain independence Losmapimod shown to improve or preserve function as measured by RWS in two...
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 11, 2022 08:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., March 11, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics® Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results
March 03, 2022 07:01 ET
|
Fulcrum Therapeutics, Inc.
– Clear path forward for Phase 3 REACH trial with losmapimod in FSHD; Trial expected to begin in 2Q 2022 – – On track to report initial data from Phase 1b trial with FTX-6058 in sickle cell disease...
Fulcrum Therapeutics® Announces REACH, a Phase 3 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
March 03, 2022 07:00 ET
|
Fulcrum Therapeutics, Inc.
Reachable Workspace (RWS) primary endpoint based on discussions with FDA and EU regulatory agencies Trial expected to begin in 2Q 2022Potential first-to-market therapy for FSHDFulcrum to host virtual...
Fulcrum Therapeutics® to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Thursday, March 3, 2022 at 8:00 a.m. ET
February 24, 2022 08:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 11, 2022 08:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics® to Participate in 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022 08:00 ET
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics® Announces Upcoming Milestones to Support Its Mission of Treating the Root Cause of Rare Genetic Diseases
January 10, 2022 07:00 ET
|
Fulcrum Therapeutics, Inc.
First patient dosed in Phase 1b trial of FTX-6058 in sickle cell disease; Initial data expected in 2Q 2022 Submitted IND for FTX-6058 to support initiation of Phase 1b trial in select...